Alliance Global Partners Upgrades Qualigen Therapeutics (QLGN) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts QLGN Hot Sheet
Price: $3.21 --0%
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Join SI Premium – FREE
Alliance Global Partners analyst James Molloy upgraded Qualigen Therapeutics (NASDAQ: QLGN) from Hold to Buy with a price target of $10.00.
For an analyst ratings summary and ratings history on Qualigen Therapeutics click here. For more ratings news on Qualigen Therapeutics click here.
Shares of Qualigen Therapeutics closed at $4.70 yesterday.
You May Also Be Interested In
- Compass Point Upgrades Circle Internet Group (CRCL) to Buy, 'a tactical trade into YE2026 and 4Q26 results'
- Goldman Sachs Upgrades Saudi Tadawul Group (1111:SE) to Buy
- Canaccord Upgrades Joby Aviation Inc (JOBY) to Buy
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
